Novel ALK inhibitors in clinical use and development

被引：0
作者：
Chaitanya Iragavarapu
Milaim Mustafa
Akintunde Akinleye
Muhammad Furqan
Varun Mittal
Shundong Cang
Delong Liu
机构：
[1] Westchester Medical Center and New York Medical College,Department of Medicine
[2] University of Iowa Carver College of Medicine,Department of Medicine, Division of Hematology and Oncology
[3] Albert Einstein Medical Center,Department of Medicine, Division of Hematology/Oncology
[4] Zhengzhou University,Department of Oncology, Henan Province People’s Hospital|
[5] Zhengzhou University,Henan Cancer Hospital
来源：
Journal of Hematology & Oncology | / 8卷
关键词：
Anaplastic lymphoma kinase; ALK-1; Crizotinib; Ceritinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in the pathogenesis of non-small cell lung cancer (NSCLC) and other solid tumors. Multiple small molecule inhibitors with activity against ALK and related oncoproteins are under clinical development. Two of them, crizotinib and ceritinib, have been approved by FDA for treatment of locally advanced and metastatic NSCLC. More agents (alectinib, ASP3026, X396) with improved safety, selectivity, and potency are in the pipeline. Dual inhibitors targeting ALK and EGFRm (AP26113), TRK (TSR011), FAK (CEP-37440), or ROS1 (RXDX-101, PF-06463922) are under active clinical development.
引用
收藏
相关论文
共 599 条
  • [1] Orscheschek K(1995)Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin’s disease: indication of a common pathogenesis? Lancet 345 87-90
  • [2] Merz H(1990)Signal transduction by receptors with tyrosine kinase activity Cell 61 203-212
  • [3] Hell J(2013)Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition Pharmacol Res 68 68-94
  • [4] Binder T(1994)Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas Cancer Res 54 2873-2877
  • [5] Bartels H(2002)ALK protein expression in rhabdomyosarcomas Histopathology 41 461-467
  • [6] Feller AC(2002)Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases Mod Pathol 15 931-938
  • [7] Ullrich A(2008)Oncogenic mutations of ALK kinase in neuroblastoma Nature 455 971-974
  • [8] Schlessinger J(2008)EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas Lung Cancer 61 163-169
  • [9] Roskoski R(1995)Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma Science 267 316-317
  • [10] Bullrich F(2003)ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases Blood 102 2642-2644
12345678910